» Articles » PMID: 32029445

Neuropeptide Regulation of Secretion and Inflammation in Human Airway Gland Serous Cells

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2020 Feb 8
PMID 32029445
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Airway submucosal gland serous cells are sites of expression of the cystic fibrosis transmembrane conductance regulator (CFTR) and are important for fluid secretion in conducting airways. To elucidate how neuropeptides regulate serous cells, we tested if human nasal turbinate serous cells secrete bicarbonate (HCO ), important for mucus polymerisation and antimicrobial peptide function, during stimulation with cAMP-elevating vasoactive intestinal peptide (VIP) and if this requires CFTR. Serous cells stimulated with VIP exhibited a ∼15-20% cAMP-dependent decrease in cell volume and a ∼0.15 unit decrease in intracellular pH (pH), reflecting activation of Cl and HCO secretion, respectively. HCO secretion was directly dependent on CFTR and was absent in cells from CF patients. In contrast, neuropeptide Y (NPY) reduced VIP-evoked cAMP increases, CFTR activation, and Cl/HCO secretion. Culture of primary serous cells in a model that maintained a serous phenotype confirmed the activating and inhibiting effects of VIP and NPY, respectively, on fluid and HCO secretion. Moreover, VIP enhanced antimicrobial peptide secretion and antimicrobial efficacy of secretions while NPY reduced antimicrobial efficacy. In contrast, NPY enhanced cytokine release while VIP reduced cytokine release through a mechanism requiring CFTR. As levels of VIP and NPY are up-regulated in diseases like allergy, asthma, and chronic rhinosinusitis, the balance of these two peptides in the airway may control mucus rheology and inflammatory responses in serous cells. Furthermore, the loss of CFTR conductance in serous cells may contribute to CF pathophysiology by increasing serous cells inflammatory responses in addition to directly impairing Cl and HCO secretion.

Citing Articles

Effects of Akt Activator SC79 on Human M0 Macrophage Phagocytosis and Cytokine Production.

Lee R, Adappa N, Palmer J Cells. 2024; 13(11.

PMID: 38891035 PMC: 11171788. DOI: 10.3390/cells13110902.


Multiple Regulatory Signals and Components in the Modulation of Bicarbonate Transporters.

Kim H, Hong J Pharmaceutics. 2024; 16(1).

PMID: 38258089 PMC: 10820580. DOI: 10.3390/pharmaceutics16010078.


Loss of CFTR function is associated with reduced bitter taste receptor-stimulated nitric oxide innate immune responses in nasal epithelial cells and macrophages.

Carey R, Palmer J, Adappa N, Lee R Front Immunol. 2023; 14:1096242.

PMID: 36742335 PMC: 9890060. DOI: 10.3389/fimmu.2023.1096242.


Serum leptin and neuropeptide Y in patients with cystic fibrosis-A single center study.

Galiniak S, Podgorski R, Rachel M, Mazur A Front Med (Lausanne). 2022; 9:959584.

PMID: 36186778 PMC: 9515389. DOI: 10.3389/fmed.2022.959584.


Potential cellular endocrinology mechanisms underlying the effects of Chinese herbal medicine therapy on asthma.

Meng Z, Chen H, Deng C, Meng S Front Endocrinol (Lausanne). 2022; 13:916328.

PMID: 36051395 PMC: 9424672. DOI: 10.3389/fendo.2022.916328.


References
1.
Widdicombe J, Wine J . Airway Gland Structure and Function. Physiol Rev. 2015; 95(4):1241-319. DOI: 10.1152/physrev.00039.2014. View

2.
Chandrasekharan B, Nezami B, Srinivasan S . Emerging neuropeptide targets in inflammation: NPY and VIP. Am J Physiol Gastrointest Liver Physiol. 2013; 304(11):G949-57. PMC: 3680683. DOI: 10.1152/ajpgi.00493.2012. View

3.
Dhooghe B, Noel S, Huaux F, Leal T . Lung inflammation in cystic fibrosis: pathogenesis and novel therapies. Clin Biochem. 2014; 47(7-8):539-46. DOI: 10.1016/j.clinbiochem.2013.12.020. View

4.
Worthington E, Tarran R . Methods for ASL measurements and mucus transport rates in cell cultures. Methods Mol Biol. 2011; 742:77-92. DOI: 10.1007/978-1-61779-120-8_5. View

5.
Li S, Koziol-White C, Jude J, Jiang M, Zhao H, Cao G . Epithelium-generated neuropeptide Y induces smooth muscle contraction to promote airway hyperresponsiveness. J Clin Invest. 2016; 126(5):1978-82. PMC: 4855915. DOI: 10.1172/JCI81389. View